Dual targeting of MEK and Erk5 using Trametinib plus XMD8-92 inhibited the growth of NRAS-mutant melanoma cells and repressed tumor progression in NRAS-mutated melanoma xenografts [148]. Here, NRAS is linked to neoplasm.